

Pomegranate Tincture (*Punica granatum L.*) Showing Antiangiogenic Activity on Chicken Egg embryo CAM Assay

Miss. Smruti H. Rathod¹, Mr. Vaibhav Deshpande², Mr. Somesh S. Bhandare³,

Mr. Aditya G. Kadam⁴, Mr. Satyam T. Shinde⁵

^{1,3,4,5} Student of B Pharm Final Year

² Assistance Professor, Department of Pharmaceutics

Ishwar Deshmukh Institute of Pharmacy, Digras Maharashtra

Abstract: Angiogenesis, the physiological process through which new blood vessels form from pre-existing vessels, is essential for growth and development, but it also plays a critical role in pathological conditions such as cancer, diabetic retinopathy, and rheumatoid arthritis. Inhibiting angiogenesis is considered a promising therapeutic approach, particularly in cancer, where tumor growth and metastasis depend heavily on neovascularization. Natural plant-derived compounds have attracted significant interest in recent years due to their potential antiangiogenic properties and relatively low toxicity. *Punica granatum* (pomegranate) is a widely consumed fruit known for its antioxidant, anti-inflammatory, and anticancer properties, primarily attributed to its rich content of polyphenols, including punicalagins, ellagic acid, and anthocyanins. This study aims to evaluate the antiangiogenic activity of *Punica granatum* extract using the Chick Chorioallantoic Membrane (CAM) assay, a well-established in vivo model for studying angiogenesis. Fertilized chicken eggs were incubated and on the 7th day of embryonic development, sterile filter paper discs soaked in varying concentrations of pomegranate extract were placed on the CAM surface. After 72 hours of incubation, the CAMs were harvested and examined under a stereomicroscope to assess the degree of vascularization. Quantitative analysis was performed by counting the number of blood vessel branch points in treated versus control groups. The results showed a concentration-dependent inhibition of angiogenesis in the CAMs treated with *Punica granatum* extract. Higher concentrations of the extract resulted in a significant reduction in the number and complexity of blood vessels compared to the control group. This suggests that *Punica granatum* possesses potent antiangiogenic properties, potentially through the downregulation of pro-angiogenic factors or through antioxidant-mediated inhibition of endothelial cell proliferation and migration.

Keywords: *Punica granatum*, angiogenesis, chorioallantoic Membrane Assay, antiangiogenic

I. INTRODUCTION

Angiogenesis is the combination of two Greek word “Angion” and “Genesis” means “vase” and “the birth” respectively. This name is given to the particular growth of new blood capillaries from pre-existing blood vessels plexus. This process is essential to fulfill the nourishment and other damage of tissue. It is common and most important process in formation and development of vessels, so it is supportive in healing of wound granulation tissue.[1]

The anticancer effect of pomegranate fruit has been associated, at least in part, to a large number of biologically active phytochemicals which are present in the fruit. These effect of pomegranate fruit are considered due to their abilities to contract, disease and also repair damage due to antioxidative stress and inflammation. Tree, fruits, leaves and bark skin of this fruit have been used for various ailments and some other uses like in tanning industry.[2]

The various disease against which pomegranate extract is useful for prevention are prostate cancer, lymphoma, prostate hyperplasia, oxidative stress in diabetic hemodialysis, diabetes, rhinovirus infection and common cold, Acquired Immune Deficiency Syndrome (AIDS), cardiovascular protection and atherosclerosis.[3]



Pomegranate fruit extract gives about 16% vitamin C of an adult's daily need. It consists of Potassium, Vitamin B5 and polyphenols which are tannins and flavonoids [4]. Pomegranate fruit extract is rich in polyphenols which are hydrolysable tannins called ellagitannins [5]. Other phytochemicals which are present in pomegranate contain gallic acid, polyphenolic catechins and anthocyanins like delphinidins, prodelfinidin, pelargonidins and cyanidin[6]. To observe the development of blood vessels, Chick Chorioallantoic Membrane Assay model is very helpful to precede research as it is impossible in other mammalian system[7]. The Chorioallantoic membrane (CAM) is an extra developing membrane which is generally used in research studies of both processes angiogenesis and antiangiogenesis[8]. The evaluation of angiogenic and antiangiogenic effect of tested material can easily be done through CAM in short time of 24 hours[9], hence the model quickly and accurately explain both angiogenic and antiangiogenic characteristics of various chemical and natural extracts. Present study was aimed to identify the effect of Punica granatum fruit tincture on angiogenesis with the help of CAM (Chorioallantoic Membrane Assay).

POMEGRANATE (*Punica granatum* L.):

Pomegranate (*Punica granatum* L.) belong to the Punicaceae family. Its is specifically known for its nutritional & medicinal properties. Pomegranate is widely distributed around the world and therefore have the broad genetic diversity, resulting in differences in their phytochemical composition. The scientific community has focused on positive health effect of pomegranate as a whole but the different varieties have rarely been compared according to their bioactive compounds and bioactivity.[10]

Plant Profile

Synonym:- Anar, Dalimb.

Biological Name:- *Punica Granatum* L. Family :- Punicaceae

Sugars (Fructose, Glucose), Pectin, Organic Acids, Flavonoids.

CHEMICAL CONSTITUENTS OF POMEGRANATE:

Chemical constituents which shows antiangiogenic activity are:

1. Luteolin
2. Quercetin
3. Kaempferol

Luteolin

It blocks the activation of VEGF receptor. The receptor which plays the vital role in angiogenesis and lymphangiogenesis (lymphatic vessels formation).

Quercetin

It shows action by inhibiting the signaling pathways VEGFR2, MEK/ERK, PI3K/AKT & MEK/JNK.

Kaempferol

Mainly targeted on VEGFR2 and inhibit angiogenesis

Angiogenesis and Cancer: A Dynamic Interplay

Cancer growth is intricately linked to angiogenesis. This phenomenon is not just a hallmark of cancer but a fundamental enabler of tumour survival and expansion. Tumours, much like normal tissues, require a steady supply of oxygen and nutrients to sustain their rapid proliferation. Angiogenesis fulfils this need by developing an extensive vascular network that infiltrates the tumour, providing the necessary sustenance and even a route for metastasis, where cancer cells spread to other parts of the body [14,15]. Over a dozen proteins and a variety of smaller molecules have been identified as "angiogenic" signals, released by tumours to kickstart angiogenesis. Key players in this process include VEGF and bFGF. These angiogenic factors act as growth signals, prompting endothelial cells to not only divide and move towards the source of the signal but also to transform into complex tubular structures essential for new blood vessel formation [16]. Tumour-induced inflammation and oxidative stress also participate in initiating pathological angiogenesis. When macrophages and neutrophils infiltrate the tumour microenvironment, they release pro-inflammatory cytokines,



chemokines and Reactive Oxygen Species (ROS). These factors stimulate the production of angiogenic molecules, including VEGF and bFGF, leading to the development of abnormal vasculature. Furthermore, chronic inflammation and oxidative stress contribute to the creation of a hypoxic tumour environment, which activates signalling pathways like MAPK/ERK and stabilises hypoxia-inducible factor-1 alpha (HIF-1 α), further upregulating the expression of angiogenic factors. This interplay between inflammation, oxidative stress and angiogenesis not only promotes tumour growth but also contributes to metastasis, becoming a significant area of study for developing anti-cancer therapies [17]. The concept of targeting angiogenesis for cancer therapy emerged in the 1970s, pioneered by Judah Folkman, who hypothesised that cutting off a tumour's blood supply could inhibit its growth. This revolutionary idea shifted the paradigm of cancer treatment, leading to the development of antiangiogenic drugs designed to thwart the formation of new blood vessels [18]. These therapies aim to starve the tumour by blocking the signalling pathways that promote vascular growth, such as the VEGF pathway. An example of an antiangiogenic agent used in clinical practice since 2004 is Bevacizumab (Avastin, developed by Genentech), a humanised recombinant monoclonal antibody directed toward VEGF (rhu Anti-VEGF Mab) [19]. Despite the theoretical promise of antiangiogenic strategies, their practical application has faced challenges [20]. One significant issue is that these therapies are often administered after cancer has already progressed, by which time the tumour has developed sophisticated mechanisms to adapt and survive. Additionally, tumours can become resistant to antiangiogenic treatments, finding alternative pathways to continue their growth and spread [21]. Moreover, the dynamic interplay between angiogenesis and cancer is not a one-way street. Tumours actively influence their surroundings, creating an environment that fosters angiogenesis. They release various growth factors and enzymes that degrade the extracellular matrix, making it easier for new blood vessels to sprout. This bidirectional interaction highlights the complexity of the tumour microenvironment and underscores the importance of understanding the various factors that promote or inhibit angiogenesis. It also emphasises the need for more nuanced approaches to overcoming cancer resistance mechanisms, particularly in relation to antiangiogenic therapies [22].

Recent research has also explored the potential of integrating antiangiogenic therapies with other treatment modalities. For instance, combining these therapies with immunotherapy, which harnesses the body's immune system to fight cancer, has shown promising results. By disrupting the blood supply to the tumour, antiangiogenic drugs can enhance the efficacy of immunotherapies, making it harder for the tumour to evade immune detection and destruction [23].

Bioactive Compounds in Pomegranate: Antiangiogenic and Therapeutic Potential

Pomegranate fruit is abundant in bioactive compounds that exhibit promising antiangiogenic properties. Notable molecules include ellagitannins (such as punicalagin, punicalin and ellagic acid), flavonoids including anthocyanins, flavonols (quercetin and kaempferol) and flavones (luteolin glycosides), fatty acids and polysaccharides. These compounds also exhibit antioxidant and anti-inflammatory activities, further contributing to their antiangiogenic effects [24].

Flavonoids

Flavonoids, abundant in vegetables, fruits and certain beverages, serve as potent secondary metabolites with diverse health benefits. They exhibit antioxidant, anti-inflammatory, neuroprotective, cardioprotective, antiviral and antibacterial properties [25]. Notably, flavonoids are under investigation for their potential in cancer prevention by targeting endothelial cells and modulating angiogenesis. Indeed, several flavonoids have demonstrated efficacy in inhibiting angiogenesis and metastasis by regulating multiple signalling pathways. They affect the expression of key factors such as VEGF, bFGF, HIF-1 α , MMPs and VEGFR, while also inhibiting NF- κ B, PI3K/AKT/mTOR and MAPK/ERK signalling pathways.

Additionally, flavonoids play a role in adjusting endothelial cell proliferation and migration [26].

Kaempferol and quercetin, both flavonols present in pomegranate, exhibit significant anti-cancer properties. Kaempferol disrupts cancer cell VEGF release and reduces VEGF-stimulated cell viability by downregulating PI3K/AKT/mTOR and MAPK/ERK pathways [27]. Furthermore, kaempferol potentiates phosphorylation of endothelial Nitric Oxide Synthase (eNOS) and VEGFR-2 in endothelial cells [28]. Quercetin inhibits angiogenesis in human retinal endothelial cells by targeting the VEGFR2, MAPK/ERK, PI3K/AKT/mTOR and MAPK/JNK pathways



[29]. Lastly, luteolin suppresses VEGF expression via HIF-1 α - dependent mechanisms and inhibits ROS production [30]. It also reduces MMP-1 and MMP-9 expression, contributing to decreased angiogenesis in gastric cancer [31]. Pomegranate-derived oestrogenic flavonoids, including luteolin, quercetin and kaempferol, have been suggested to inhibit angiogenesis through multiple mechanisms. These include downregulating the expression of angiogenic growth factors, disrupting key cellular signalling pathways like PI3K/AKT/mTOR, and exerting antioxidant effects that reduce oxidative stress [32].




Fig.(1). Pomegranate Exhibiting Medicinal Properties

II. METHOD AND MATERIALS

Method I: Tincturing fresh plant material when using 190 proof alcohol.

1. Chop the fresh plant into small pieces and stuff them into a canning jar, filling it to the top.
2. Pack the herb into the jar very tightly.
3. Get as much into the jar as you can, especially when working with a light herb.
4. Add 190-proof ethyl alcohol, filling the jar to the top. Make sure all herb is covered by the alcohol.
5. Cap jar tightly.
6. Agitate the jar frequently for 14 days.
7. Decant the liquid, press the remaining wet pulp & combine these two liquid.
8. Filter if desired % Bottle, tightly cap and label.

Method II: Tincturing fresh plant material when using diluted alcohol (less than 190-proof).

1. Chop the fresh plant into small pieces and stuff them into a canning jar, filling it to the top.
2. Add menstruum (the easiest method to obtain is probably a commercial 80-proof or 100proof vodka. Eighty-proof vodka is approximately 40% alcohol by volume; 100 proof is approximately 50% alcohol by volume. 20-30% alcohol is sufficient to preserve a tincture. Therefore, when making a dried plant preparation, 80-proof vodka is adequate. When making a fresh plant preparation, which always incorporates the juices of the plant [which dilute the menstruum], maybe 100-proof vodka is more judicious).



3. Pour the entire ingredients (herb and menstruum) into a Vita-Mix or some other suitable blender and blend it like a smoothie. (you will have to make a large enough batch, so that the volume of menstruum required is sufficient to completely cover the blender blades).
4. Pour the liquefied ingredients into a jar and cap tightly.
5. Agitate tincture frequently for 14 days, then let it sit another day.
6. Decant, press filter % bottle tightly cap and label.[33]



Day 01



Day 14

EVALUATION OF POMEGRANATE TINCTURE

1. Organoleptic Test.

Test	Observation	Inference
Colour	Slightly pink	Positive
Aroma	Fruity, characteristic smell	Positive
Taste	Astringent, slightly sweet	Positive
Sedimentation	Absent	Positive
Clarity	Clear or slightly cloudy	Positive


2. Physicochemical Evaluation

Parameter	Test	Result
pH	pH meter	4.0
Alcohol content(%)	Alcoholometry	40%
Specific Gravity	Hydrometer	1.5

3. Identification Test of Flavonoids

Test	Observation	Inference	
1. Shinoda test (Magnesium Hydrochloride Reaction) Sample+magnesium turning+conc.hcl	Appearance of reddish colour.	Confirm presence of Flavonoids.	
2. Alkali Reagent Test Leadacetate solution+sample	Formation of yellow colour .	Confirm presence of Flavonoids	






Test Observation Inference

1. Shinoda test (Magnesium Hydrochloride Reaction) Sample+magnesium turning+conc.hcl Appearance of reddish colour. Confirm presence of Flavonoids.
2. Alkali Reagent Test Leadacetate solution+sample Formation of yellow colour . Confirm presence of Flavonoids

III. RESULTS



In the present study we have observed the effect of pomegranate on angiogenesis using chicken Chorioallantoic membrane (CAM) assay. After the application of pomegranate tincture decrease in formation of blood vessels was observed as compared to control group. When we applied tincture on CAM, these caused clear changes in blood vasculature of the CAM. Antiangiogenic activities (reduction in blood vessels) were seen after the introduction of fruit, which showed a perceptible reduction in the overall length and diameter.



Length of Blood Vessels(cm)

Parameter	Group A	Group B	Group C
Controlled	0.4231	0.6263	0.8323
Treated	0.4010	0.5925	0.7926





III. CONCLUSION

Extensive evidence underscores the significant antiangiogenic potential of pomegranate extracts, positioning them as promising candidates for the prevention and treatment of cancer and other angiogenesis-related diseases. This potential is primarily attributed to their rich content of polyphenols, punical acid and bioactive polysaccharides, which modulate key molecular targets such as HIF-1 α , VEGF, Sp, specific microRNAs and various inflammatory mediators. Beyond their antiangiogenic properties, the diverse bioactive compounds found in various parts of the pomegranate—such as juice, peels, kernels and roots—contribute to a wide range of biological activities, including anti-inflammatory, antioxidant and pro-apoptotic effects. These activities collectively inhibit neovascularization, potentially reducing tumour growth.

REFERENCES

- [1]. Eliseenko, V.I; O.K. Skobelkin, V.M. Chegin and M.K. Degtyarev, 1998. Microcirculation and angiogenesis during wound healing by first and second intention. Bull. Exp. Bio. Med, 105: 289-292.
- [2]. Rania, J; H. Ne'jib, M. Messaoud, M. Mohamed and T. Mokhtar, 2007. Characterization of Tunisian pomegranate (*Punica granatum* L.) cultivars using amplified fragment length polymorphism analysis, Scientia Horticulturae, available online.
- [3]. Aviram, M; L. Dornfeld, M. Rosenblat, N. Volkova, M. Kaplan, R. Coleman, T. Hayek, D. Presser and B. Fuhrman, 2000. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am. J.



Clin. Nutr,71: 1062 1076.

- [4]. Schubert, S.Y; E.P. Lansky and I. Neeman, 1999. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J. ethnopharmacol, 66 (1): 11-17.
- [5]. Passamonti, S; U. Vrhovsek, A. Vanzo and F. Mattivi, 2003. Their Relation to Some of Their Pomological and the stomach as a site for and Phytonutrient Characteristics. Molecules, anthocyanins absorption from food, FEBS Letters, 14: 1808-1817.
- [6]. Plumb, G.W; S. De Pascual-teresa, C. Santos-bulega, J.C. Rivas-gonzalo and G. Williamsons, 2002. "Antioxidant properties of gallo catechins and prodelphinidins from pomegranate peel". Redox. rep, 7 (41): 41.
- [7]. Colangelo, A.M; M.R. Bianco, L. Vitagliano, C. Cavaliere, G. Cirillo, D.E.L. Gioia, D. Diana, D. Colombo, C. Redaelli, L. Zaccaro, G. Morelli, M. Papa, P. Sarmientos, L. Alberghina and E. Martegani, 2008. A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. J. Neurosci, 28, 2698-709.
- [8]. Cao, Y, 2007. Angiogenesis modulates adipogenesis and obesity. Journal of Clinical Investigation, 117(9): 2362.
- [9]. Ribbati, D; C. Urbinati, B. Nico, M. Rusnati, L. Roncali and M. Presta, 1995. Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick chorioallantoic membrane. Dev. Biol, 170(1): 39-49
- [10]. Melgarejo-Sánchez, P., Núñez-Gómez, D., Martínez-Nicolás, J.J. et al. Pomegranate variety and pomegranate plant part, relevance from bioactive point of view: a review. Bioresour. Bioprocess. 8, 2 (2021). <https://doi.org/10.1186/s40643-020-00351-5>
- [11]. Aguilar-Cazares, D.; Chavez-Dominguez, R.; Carlos-Reyes, A.; Lopez-Camarillo, C.; Hernandez de la Cruz, O.N.; Lopez-Gonzalez, J.S. Contribution of Angiogenesis to Inflammation and Cancer. Front. Oncol. 2019, 9, 1399.
- [12]. Albini, A.; Noonan, D.M.; Corradino, P.; Magnoni, F.; Corso, G. The Past and Future of Angiogenesis as a Target for Cancer Therapy and Prevention. Cancer Prev. Res. 2024, 17, 289–303.[CrossRef][PubMed]
- [13]. Liu, Z.L.; Chen, H.H.; Zheng, L.L.; Sun, L.P.; Shi, L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Sig. 12.Transduct. Target. Ther. 2023, 8, 198. [CrossRef]
- [14]. Chaudhary, P.; Janmeda, P.; Docea, A.O.; Yeskalyeva, B.; Abdull Razis, A.F.; Modu, B.; Calina, D.; Sharifi-Rad, J. Oxidative stress, free radicals and antioxidants: Potential crosstalk in the pathophysiology of human diseases. Front. Chem. 2023, 11, 1158198.
- [15]. Ribatti, D. Judah Folkman, a pioneer in the study of angiogenesis. Angiogenesis 2008,11, 3–10. [CrossRef]
- [16]. Quesada, A.R.; Muñoz-Chápuli, R.; Medina, M.A. Anti-angiogenic drugs: From bench to clinical trials. Med. Res. Rev. 2006, 26, 483–530. [CrossRef] [PubMed]
- [17]. Lopes-Coelho, F.; Martins, F.; Pereira, S.A.; Serpa, J. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. Int. J.Mol. Sci. 2021, 22, 3765. [CrossRef] [PubMed]
- [18]. Haibe, Y.; Kreidieh, M.; El Hajj, H.; Khalifeh, I.; Mukherji, D.; Temraz, S.; Shamseddine, A. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. Front. Oncol. 2020, 10, 221. [CrossRef] [PubMed]
- [19]. Jiang, X.; Wang, J.; Deng, X.; Xiong, F.; Zhang, S.; Gong, Z.; Li, X.; Cao, K.; Deng, H.; He, Y.; et al. The role of microenvironment in tumor angiogenesis. J. Exp. Clin. Cancer Res. 2020, 39, 204. [CrossRef] [PubMed]
- [20]. Furukawa, K.; Nagano, T.; Tachihara, M.; Yamamoto, M.; Nishimura, Y. Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer. Molecules 2020, 25, 3900. [CrossRef] [PubMed]
- [21]. Malabadi, R.B.; Sadiya, M.R.; Kolkar, K.P.; Mammadova, S.S.; Chalannavar, R.K.; Baijnath, H. Role of Plant derived-medicine for controlling Cancer. Int. J. Sci. Res. Arch. 2024, 11, 2502–2539. [CrossRef]
- [22]. Rahimi, H.R.; Arastoo, M.; Ostad, S.N. A Comprehensive Review of Punica granatum (Pomegranate) Properties in Toxicological, Pharmacological, Cellular and Molecular Biology Researches. Iran. J. Pharm. Res. 2012, 11, 385–400. [PubMed]



- [23]. Khan, G.J.; Omer, M.O.; Ashraf, M.; Rehman, H.U.; Khan, Z.U.D. Effect of Punica granatum (pomegranate) fruit extract on angiogenesis. *J. App. Pharm.* 2013, 4, 764–780.
- [24]. Shih, P.H.; Yeh, C.T.; Yen, G.C. Anthocyanins Induce the Activation of Phase II Enzymes through the Antioxidant Response Element Pathway against Oxidative Stress- Induced Apoptosis. *J. Agric. Food Chem.* 2007, 55, 9427–9435. [CrossRef] [PubMed]
- [25]. Kim, Y.E.; Hwang, C.J.; Lee, H.P.; Kim, C.S.; Son, D.J.; Ham, Y.W.; Hellström, M.; Han, S.B.; Kim, H.S.; Park, E.K.; et al. Inhibitory effect of punicalagin on lipopolysaccharide-induced neuroinflammation, oxidative stress and memory impairment via inhibition of nuclear factor-kappaB. *Neuropharmacology* 2017, 117, 21–32. [CrossRef] [PubMed]
- [26]. Chin, H.K.; Horng, C.T.; Liu, Y.S.; Lu, C.C.; Su, C.Y.; Chen, P.S.; Chiu, H.Y.; Tsai, F.J.; Shieh, P.C.; Yang, J.S. Kaempferol inhibits angiogenic ability by targeting VEGF receptor-2 and downregulating the PI3K/AKT, MEK and ERK pathways in VEGF- stimulated human umbilical vein endothelial cells. *Oncol. Rep.* 2018, 39, 2351–2357. [CrossRef] [PubMed]
- [28]. Hu, W.H.; Wang, H.Y.; Xia, Y.T.; Dai, D.K.; Xiong, Q.P.; Dong, T.T.; Duan, R.; Chan, G.K.; Qin, Q.W.; Tsim, K.W. Kaempferol, a major flavonoid in Ginkgo folium, potentiates angiogenic functions in cultured endothelial cells by binding to vascular endothelial growth factor. *Front. Pharmacol.* 2020, 11, 526. [CrossRef] [PubMed]
- [29]. Lupo, G.; Cambria, M.T.; Olivieri, M.; Rocco, C.; Caporarello, N.; Longo, A.; Zanghi, G.; Salmeri, M.; Foti, M.C.; Anfuso, C.D. Anti-angiogenic effect of quercetin and its 8- methyl pentamethyl ether derivative in human microvascular endothelial cells. *J. Cell Mol. Med.* 2019, 23, 6565–6577. [CrossRef] [PubMed]
- [30]. Park, S.W.; Cho, C.S.; Jun, H.O.; Ryu, N.H.; Kim, J.H.; Yu, Y.S.; Kim, J.S.; Kim, J.H. Anti-angiogenic effect of luteolin on retinal neovascularization via blockade of reactive oxygen species production. *Investig. Ophthalmol. Vis. Sci.* 2012, 53, 7718– 7726. [CrossRef] [PubMed]
- [31]. Pervin, M.; Unno, K.; Nakamura, Y.; Imai, S. Luteolin Suppresses Ultraviolet A- and B- induced matrix metalloproteinase 1- and 9 expression in human dermal fibroblast cells. *J. Nutr. Food Sci.* 2016, 6, 560. [CrossRef]
- [32]. Zang, M.; Hu, L.; Zhang, B.; Zhu, Z.; Li, J.; Zhu, Z.; Yan, M.; Liu, B. Luteolin suppresses angiogenesis and vasculogenic mimicry formation through inhibiting Notch1- VEGF signaling in gastric cancer. *Biochem. Biophys. Res. Commun.* 2017, 490, 913– 919. [CrossRef]
- [33]. Wang, Y.; Huang, M.; Zhou, X.; Li, H.; Ma, X.; Sun, C. Potential of natural flavonoids to target breast cancer angiogenesis (review). *Br. J. Pharmacol.* 2023, 1–24
- [34]. The Herbal Medicine-Maker's Handbook by James Green (for tincture preparation methods)

